[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ME00546B - Korišćenje inhibitora il-18 - Google Patents

Korišćenje inhibitora il-18

Info

Publication number
ME00546B
ME00546B MEP-2008-639A MEP63908A ME00546B ME 00546 B ME00546 B ME 00546B ME P63908 A MEP63908 A ME P63908A ME 00546 B ME00546 B ME 00546B
Authority
ME
Montenegro
Prior art keywords
medicaments
prevention
preparation
treatment
present
Prior art date
Application number
MEP-2008-639A
Other languages
English (en)
Inventor
Yolande Chvatchko
Charles Dinarello
Zyberk Christine Plater
DEVENTER Santer VAN
Menachem Rubinstein
Daniela Novick
Soo Hyun Kim
Original Assignee
Serono Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serono Lab filed Critical Serono Lab
Publication of ME00546B publication Critical patent/ME00546B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Addiction (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Ovaj pronalazak se odnosi na korišćenje inhibitora IL- i 8 za pripremu medikamenata za tretman i/ili prevenciju oštećenja jetre. Ovaj pronalazak se dalje odnosi na korišćenje inhibitora IL.18 za pripremu medikamenata za lečenje i/ili prevenciju artritisa, posebno reumatoidnog artritisa. Uz to, ovaj pronalazak se odnosi na korišćenje inhibitora IL-18 za pripremu medikamenata za lečenje i/ili prevenciju zapaljenske bolesti creva, pre svih Kronove bolesti i ulceroznog kolitisa. Ovaj pronalazak se odnosi na korišćenje inhibitora IL- i 8 za pripremu medikamenata za tretman i/ili prevenciju oštećenja jetre. Ovaj pronalazak se dalje odnosi na korišćenje inhibitora IL.18 za pripremu medikamenata za lečenje i/ili prevenciju artritisa, posebno reumatoidnog artritisa. Uz to, ovaj pronalazak se odnosi na korišćenje inhibitora IL-18 za pripremu medikamenata za lečenje i/ili prevenciju zapaljenske bolesti creva, pre svih Kronove bolesti i ulceroznog kolitisa.
MEP-2008-639A 2000-02-21 2001-02-20 Korišćenje inhibitora il-18 ME00546B (me)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP00103590 2000-02-21
EP00103597 2000-02-21
EP00121651 2000-10-04
EP00125633 2000-11-23
PCT/EP2001/001867 WO2001062285A1 (en) 2000-02-21 2001-02-20 Use of il-18 inhibitors

Publications (1)

Publication Number Publication Date
ME00546B true ME00546B (me) 2011-10-10

Family

ID=27439934

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2008-639A ME00546B (me) 2000-02-21 2001-02-20 Korišćenje inhibitora il-18

Country Status (31)

Country Link
US (1) US20030157094A1 (me)
EP (1) EP1257292B1 (me)
JP (1) JP4744763B2 (me)
KR (3) KR20020086540A (me)
CN (1) CN1322897C (me)
AT (1) ATE506959T1 (me)
AU (2) AU4063601A (me)
BG (1) BG66134B1 (me)
BR (1) BR0108514A (me)
CA (2) CA2683009C (me)
CY (1) CY1111687T1 (me)
CZ (1) CZ304485B6 (me)
DE (1) DE60144514D1 (me)
DK (1) DK1257292T3 (me)
EA (1) EA005583B1 (me)
EE (1) EE05423B1 (me)
HK (1) HK1051965A1 (me)
HR (1) HRP20020652A2 (me)
HU (1) HU227752B1 (me)
IL (2) IL151388A0 (me)
ME (1) ME00546B (me)
MX (1) MXPA02008079A (me)
NO (1) NO331971B1 (me)
NZ (3) NZ520122A (me)
PL (1) PL206549B1 (me)
PT (1) PT1257292E (me)
RS (1) RS51737B (me)
SI (1) SI1257292T1 (me)
SK (1) SK288032B6 (me)
TR (2) TR200502508T2 (me)
WO (1) WO2001062285A1 (me)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101111103B1 (ko) * 2000-02-10 2012-02-13 아보트 러보러터리즈 사람 인터류킨-18에 결합하는 항체 및 이를 제조하고 사용하는 방법
CN1322897C (zh) * 2000-02-21 2007-06-27 应用研究系统Ars股份公司 Il－18抑制剂的应用
AU2002211744B8 (en) 2000-10-11 2008-03-20 Viron Therapeutics, Inc. Nucleic acid molecules and polypeptides for immune modulation
US7718368B2 (en) 2000-12-04 2010-05-18 Viron Therapeutics Inc. Immunomodulatory protein and useful embodiments thereof
ES2334773T3 (es) * 2001-05-16 2010-03-16 Yeda Research And Development Co. Ltd. Uso de inhibidores de il-18 para el tratamiento o prevencion de la sepsis.
MXPA04002565A (es) * 2001-11-30 2004-05-31 Pfizer Prod Inc Combinacion de un inhibidor de il-1/18 con un inhibidor de tnf para el tratamiento de inflamacion.
WO2004064713A2 (en) * 2003-01-20 2004-08-05 Vib Vzw The use of yop preoteins or rho gtpase inhibitors as caspase-1 inhibitors
JP4134166B2 (ja) 2003-04-30 2008-08-13 独立行政法人科学技術振興機構 ヒト抗ヒトインターロイキン−１８抗体およびその断片、並びにそれらの利用方法
WO2005047906A1 (en) * 2003-11-10 2005-05-26 Vertex Pharmaceuticals Incorporated Methods for monitoring il-18
US7968684B2 (en) * 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
JP5069000B2 (ja) 2004-06-30 2012-11-07 敦生 関山 非炎症性ストレス応答の指標剤およびその利用
JP5595632B2 (ja) 2004-07-16 2014-09-24 敦生 関山 Ｉｌ−１８レセプターアンタゴニスト、および当該アンタゴニストを含む薬学的組成物
DK1885753T3 (da) 2005-06-03 2011-10-03 Ares Trading Sa Fremstilling af rekombinant II-18-proteiner
PT1891088E (pt) 2005-06-10 2011-12-19 Ares Trading Sa Processo para a purificação da proteína de ligação il-18
EP1746167A1 (en) * 2005-07-20 2007-01-24 Apoxis SA Method for the identification of compounds susceptible to inhibit inflammation
US8133978B2 (en) 2006-05-25 2012-03-13 Glaxo Group Limited Humanised anti-interleukin-18 antibody
US8440195B2 (en) * 2010-11-12 2013-05-14 National University Corporation Chiba University Inhibition of CD69 for treatment of inflammatory conditions
GB201213968D0 (en) * 2012-08-06 2012-09-19 Isis Innovation Prevention and treatment of osteoarthritis
SG11201601717VA (en) * 2013-09-05 2016-04-28 Ab2 Bio Sa Il-18 binding protein (il-18bp) in inflammatory diseases
RU2755691C2 (ru) 2015-03-05 2021-09-20 Аб2 Био Са Il-18-связывающие белок (il-18bp) и антитела при воспалительных заболеваниях
CN106109497A (zh) * 2016-07-25 2016-11-16 深圳爱生再生医学科技有限公司 治疗肝硬化的干细胞制剂
CN106834449B (zh) * 2017-01-10 2019-04-30 东南大学 与原发性胆汁性胆管炎关联的白细胞介素21受体及其应用
US20210115131A1 (en) * 2018-06-14 2021-04-22 Université De Bordeaux Treatment of Placental Chronic Histiocytic Intervillositis Using an Inhibitor of Interleukin-1
WO2023286694A1 (ja) 2021-07-13 2023-01-19 国立大学法人東海国立大学機構 炎症性腸疾患を治療するための医薬組成物
CN117647645B (zh) * 2024-01-29 2024-04-12 中国人民解放军总医院第一医学中心 Lbp、atf6、m-csfr联用在制备诊断自身免疫性肝病产品中的应用及试剂盒

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985863A (en) * 1996-09-12 1999-11-16 Vertex Pharmaceuticals, Inc. Compositions and methods for decreasing IGIF and IFN-γ production by administering an ICE inhibitor
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5744451A (en) * 1995-09-12 1998-04-28 Warner-Lambert Company N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity
EP0936923B1 (en) * 1996-11-15 2003-12-17 Kennedy Institute Of Rheumatology SUPPRESSION OF TNFalpha AND IL-12 IN THERAPY
US7141393B2 (en) * 1996-12-26 2006-11-28 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18-receptor proteins
JP4026923B2 (ja) * 1997-03-12 2007-12-26 株式会社林原生物化学研究所 ポリペプチド
US6087116A (en) * 1997-03-12 2000-07-11 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18 (IL-18) receptor polypeptides and their uses
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
CA2276216A1 (en) * 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
KR100537558B1 (ko) * 1998-09-01 2005-12-19 가부시끼가이샤 하야시바라 세이부쓰 가가꾸 겐꾸조 인터류킨-18 결합 단백질
AR022952A1 (es) * 1999-03-19 2002-09-04 Smithkline Beecham Corp ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL
KR101111103B1 (ko) * 2000-02-10 2012-02-13 아보트 러보러터리즈 사람 인터류킨-18에 결합하는 항체 및 이를 제조하고 사용하는 방법
CN1322897C (zh) * 2000-02-21 2007-06-27 应用研究系统Ars股份公司 Il－18抑制剂的应用
AU2002224417A1 (en) * 2000-10-18 2002-04-29 Immunex Corporation Methods for treating il-18 mediated disorders

Also Published As

Publication number Publication date
CN1322897C (zh) 2007-06-27
TR200202030T2 (tr) 2003-01-21
SK288032B6 (sk) 2012-12-03
CA2399298A1 (en) 2001-08-30
HRP20020652A2 (en) 2004-12-31
KR20070057282A (ko) 2007-06-04
NO20023962D0 (no) 2002-08-20
NO331971B1 (no) 2012-05-14
EP1257292A1 (en) 2002-11-20
CZ20022843A3 (cs) 2003-02-12
AU2001240636B8 (en) 2005-11-03
HUP0300061A3 (en) 2005-09-28
BG107018A (bg) 2003-09-30
DE60144514D1 (de) 2011-06-09
KR20070087256A (ko) 2007-08-27
CA2683009A1 (en) 2001-08-30
CY1111687T1 (el) 2015-10-07
KR20020086540A (ko) 2002-11-18
NZ535299A (en) 2006-06-30
AU2001240636B2 (en) 2005-10-13
ATE506959T1 (de) 2011-05-15
HU227752B1 (en) 2012-02-28
MXPA02008079A (es) 2003-02-27
NO20023962L (no) 2002-08-20
IL151388A0 (en) 2003-04-10
EE05423B1 (et) 2011-06-15
TR200502508T2 (tr) 2007-04-24
PL206549B1 (pl) 2010-08-31
EA200200890A1 (ru) 2003-02-27
JP2003523403A (ja) 2003-08-05
AU4063601A (en) 2001-09-03
PT1257292E (pt) 2011-07-05
BG66134B1 (bg) 2011-06-30
WO2001062285A1 (en) 2001-08-30
SK12082002A3 (sk) 2003-05-02
JP4744763B2 (ja) 2011-08-10
US20030157094A1 (en) 2003-08-21
HUP0300061A2 (hu) 2003-04-28
CN1404400A (zh) 2003-03-19
YU60402A (sh) 2005-09-19
PL357554A1 (en) 2004-07-26
HK1051965A1 (en) 2003-08-29
NZ520122A (en) 2005-04-29
EA005583B1 (ru) 2005-04-28
NZ546294A (en) 2008-02-29
EE200200463A (et) 2003-12-15
SI1257292T1 (sl) 2011-08-31
CZ304485B6 (cs) 2014-05-28
DK1257292T3 (da) 2011-07-18
CA2683009C (en) 2014-09-23
CA2399298C (en) 2014-04-15
EP1257292B1 (en) 2011-04-27
IL151388A (en) 2009-09-01
BR0108514A (pt) 2002-12-17
RS51737B (sr) 2011-10-31

Similar Documents

Publication Publication Date Title
ME00546B (me) Korišćenje inhibitora il-18
MA27374A1 (fr) Ester de 2'-c-methyl-3'-o-l-valine et de ribofuranosyl cytidine pour le traitement des infections des flaviviridae
RS54573B1 (en) MACROCYCLIC CARBOXYLIC ACIDS AND ACYLSULPHONAMIDES AS HCV REPLICATION INHIBITORS
TR200102967T2 (tr) Substitüsyonlu azollar
DE60332433D1 (de) Azolylaminoazine als proteinkinasehemmer
DE60332604D1 (de) Azolylaminoazine als proteinkinasehemmer
DE69824037D1 (de) Beta-alanin-derivate als zell-adhäsions-inhibitoren
IS6177A (is) Samsetning af mjólkursýrugerlum og notkun hennar til að fyrirbyggja og/eða meðhöndla sýkingar og bólguástand
PT1117440E (pt) Composicoes farmaceuticas que contem paclitaxel
IT1318649B1 (it) Composizioni farmaceutiche per il trattamento di mucositi e stomatiti.
WO2001035950A3 (en) Benzamide therapeutics and methods for treating inflammatory bowel disease
BRPI0110506B8 (pt) uso de inibidores de il-18 para o tratamento e/ou prevenção da aterosclerose
ATE414526T1 (de) Zubereitungen zur behandlung von arthritischen erscheinungen
NO20035035D0 (no) Citrasalt av 5,8,14-triazatetracyklo (10.3.1.0 opphöyet 2,11 .0 opphöyet 4,9) - heksadeca-2. (11), 3,5,7,9-pentaen og farmasöytiskesammensetninger derav
MXPA04002565A (es) Combinacion de un inhibidor de il-1/18 con un inhibidor de tnf para el tratamiento de inflamacion.
ME00549B (me) Upotreba inhibitora il-18 za liječenje i/ili prevenciju srčanih oboljenja
IL144199A0 (en) Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
SE0300445D0 (sv) New combination
CY1108053T1 (el) Ενωση της κυαμεμαζινης και ενος ατυπου νευροληπτικου
RS54140B1 (en) USE OF 24-ORDER
ME00547B (me) Upotreba inhibitora il-18 kod poremećaja hipersenzitinosti (preosjetljivosti)
FR2801214B1 (fr) Utilisation en combinaison de nouvelles compositions solides et non solides pour traiter la dilatation abdominale
BR0017074A (pt) Combinações de inibidor de ace-antagonista de vasopressina
TR200502061T2 (tr) IL-18 inhibitörlerinin kullanımı.
ATE353221T1 (de) Verwendung von gegen candida wirksamen mitteln zur behandlung von störungen der oralen und intestinalen mucosa